Health Condition 1: N358- Other urethral stricture
Conditions
Interventions
Intervention1: Testosterone supplementation with self calibration: Intervention Details:
Testosterone therapy using injectable or transdermal formulations administered in hypogonadal adult male patien
Sponsors
IPGMER and SSKM HOSPITAL
Eligibility
Inclusion criteria
Inclusion criteria: Adult male patients aged 18 to 80 years with urethral stricture disease and documented low serum testosterone levels planned for definitive treatment including urethroplasty, optical internal urethrotomy, or endoscopic dilatation and willing to provide written informed consent.
Exclusion criteria
Exclusion criteria: Patients with pelvic fracture urethral distraction defect, prior pelvic irradiation, previous testosterone therapy, carcinoma prostate, severe lower urinary tract symptoms unrelated to urethral stricture disease, contraindication to testosterone therapy, or unwillingness to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of urethral stricture recurrenceTimepoint: Assessed at 3 months, 6 months, and 12 months following definitive urethral stricture treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in peak urinary flow rate (Qmax)Timepoint: Baseline, 3 months, 6 months, and 12 months;Change in International Prostate Symptom Score (IPSS)Timepoint: Baseline and 12 months;Change in post-void residual urine volumeTimepoint: Baseline, 3 months, 6 months, and 12 months;Safety and adverse effects of testosterone therapy including hematocrit and PSA changesTimepoint: During follow-up up to 12 months;Recurrence-free survival following interventionTimepoint: 12 months post-intervention | — |
Countries
India
Contacts
Public ContactDr Soumya Mondal
IPGMER and SSKM HOSPITAL
Outcome results
None listed